NEW YORK, June 30, 2016 /PRNewswire/ --
On Wednesday, June 29, 2016, the
NASDAQ Composite ended the trading session at 4,779.25, up 1.86%;
the Dow Jones Industrial Average advanced 1.64%, to finish at
17,694.68; and the S&P 500 closed at 2,070.77, up 1.70%. The
gains were broad based as all the sectors ended the session in
positive. Stock-Callers.com has initiated coverage on the following
equities: Nanosphere Inc. (NASDAQ: NSPH), SciClone Pharmaceuticals
Inc. (NASDAQ: SCLN), ConforMIS Inc. (NASDAQ: CFMS), and Momenta
Pharmaceuticals Inc. (NASDAQ: MNTA). Learn more about these stocks
by accessing their free trade alerts at:
http://stock-callers.com/registration
Nanosphere Inc. develops, manufactures, and markets molecular
diagnostic tests for infectious diseases and associated drug
resistance markers for earlier disease detection, optimal patient
treatment, and improved healthcare economics. The stock finished
Wednesday's session flat at $1.70
with a total volume of 95,245 shares traded. The Company's shares
have rallied 115.19% in the previous three months. The stock is
trading above its 50-day and 200-day moving averages by 29.85% and
45.87%, respectively. Nanosphere's stock has a Relative Strength
Index (RSI) of 79.99. Sign up and read the free notes on NSPH
at:
http://stock-callers.com/registration/?symbol=NSPH
On Wednesday, shares in Foster City,
California headquartered specialty pharmaceutical Company,
SciClone Pharmaceuticals Inc., ended the session 1.15% higher at
$13.19 with a total volume of 248,053
shares traded. Shares of the Company traded at a PE ratio of 24.29.
The Company's shares have gained 19.91% in the previous three
months and 34.32% in the past one year. The stock is trading 32.87%
above its 200-day moving average. Moreover, shares of SciClone
Pharmaceuticals have an RSI of 44.38. The complimentary notes on
SCLN can be downloaded in PDF format at:
http://stock-callers.com/registration/?symbol=SCLN
Bedford, Massachusetts
headquartered medical technology Company, ConforMIS Inc.'s stock
advanced 4.98% to close the day at $6.75 with a total volume of 270,963 shares
traded. The stock is trading 23.97% below its 50-day moving
average. Additionally, ConforMIS' stock has an RSI of 36.65.
Register for free on Stock-Callers.com and access the latest
research on CFMS at:
http://stock-callers.com/registration/?symbol=CFMS
On Wednesday, shares in Cambridge,
Massachusetts headquartered biotechnology Company, Momenta
Pharmaceuticals Inc., ended the day 3.42% higher at $10.58 with a total volume of 266,752 shares
traded. The Company's shares have advanced 14.50% in the previous
three months. The stock is trading above its 50-day moving average
by 0.92%. Furthermore, shares of Momenta Pharmaceuticals have an
RSI of 47.50. Get free access to your trade alert on MNTA at:
http://stock-callers.com/registration/?symbol=MNTA
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored
reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and
micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
SC has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer") represented by a
credentialed financial analyst [for further information on analyst
credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and
reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by SC. SC is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither SC nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company we are
covering and wish to no longer feature on our coverage list contact
us via email and/or phone between 09:30 EDT
to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street,
Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Chelmsford Park SA
